Japan Price-Setting Decision Frees Drug Makers To Release Generics
This article was originally published in PharmAsia News
Executive SummaryArmed with government-set prices, several makers of generic drugs in Japan plan to launch anti-cancer drugs through the rest of the year. Sawai Pharmaceutical released 34 as soon as the Health Ministry announced official prices, and Towa Pharmaceutical plans to introduce 14 over the next few weeks. Nichi-Iko Pharmaceutical says it plans to release 26 generics over the course of the year and Taiyo Pharmaceutical Industry plans 17. (Click here for more - a subscription may be required
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.